Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (3 ops.)
Latest filing published 30 Jun 2021 for BeiGene, Ltd., €136k. Read the official filing
Filing timeline
BuySaleHoward Liang
Insider track record
Disclosed buys
1
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Howard Liang: trading record in brief
Howard Liang (finance chief) discloses dealings in BeOne Medicines Ltd. to SEC (Form 4). Between 8 February 2016 and 28 June 2021, the trades on record add up to 4 filings.
Market trades split into 1 purchase and 3 sales (€458k). The totals do not cover 1 filing with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2021 to date brings no purchases and 3 sales.
The latest filing, published on 30 June 2021, reports an open-market sale of €136k in BeOne Medicines Ltd. The most recent open-market purchase was published on 9 February 2016, 3,903 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Howard Liang
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
446 shares@ US$365.0029.8% of flowAmerican Depositary SharesSEC:0001651308-21-000138:0
486 shares@ US$325.891929.0% of flowAmerican Depositary SharesSEC:0001651308-21-000125:0
650 shares@ US$354.157741.2% of flowAmerican Depositary SharesSEC:0001651308-21-000109:0
65,000 sharesOrdinary SharesSEC:0001104659-16-095143:0
Canonical exit: 8 May 2016 (T+90)
4 of 4 declarations
